Clinical registries and biorepositories have proven extremely useful in many studies of diseases, especially rare diseases. Given their rarity and diversity, the idiopathic inflammatory myopathies, or myositis syndromes, have benefited from individual researchers' collections of cohorts of patients. Major efforts are being made to establish large registries and biorepositories that will allow many additional studies to be performed that were not possible before. Here, we describe the registries developed by investigators and patient support groups that are currently available for collaborative research purposes.
INTRODUCTION
Clinical registries, which are organized databases of information about certain diseases, along with biorepositories, which are catalogued collections of biological specimens from patients, have been developed by many different groups for a number of purposes. Clinical registries include national administrative efforts and healthcare systems' tracking of medical utilization, costs, and outcomes, including such databases as the Social Security Death Index, from which mortality information may be gleaned [1 && ,2] or national healthcare registration systems that can be used to estimate disease prevalence in epidemiologic research [3 & ]. Registries may also include those that involve investigatorinitiated research, with data collection that may include epidemiology, clinical features, outcomes, disease activity and damage assessments, and assessment of responses to therapies. When such clinical data are linked to biospecimens, including serum, DNA, or tissue biopsy samples, they become powerful tools to explore and define disease pathogeneses, biomarkers, and genetic and environmental risk factors. Such collections of information and specimens have had a major impact in understanding the epidemiology and prognosis of various disorders, especially the rare diseases, in which progress for an individual researcher at a single center could be slow and inadequately powered, hampered by a lack of adequate patient information and specimens.
MYOSITIS REGISTRIES AND BIOREPOSITORIES
In the case of the idiopathic inflammatory myopathies, or myositis syndromes, some of the early investigator-initiated efforts in this area involved collections of systematic data on larger numbers of patients allowed some of the first careful phenotypic descriptions of these diseases and their clinical [4] and serologic [5] classifications. More recently, registries have greatly assisted in better appreciating the incidence and prevalence of myositis phenotypes in different areas [6] [7] [8] [9] 10 & ], as well as their costs and resource usage [11, 12] .
For this review, we queried myositis researchers from multiple specialties and across the globe in order to develop a catalog of clinical research registries and biorepositories that are currently available for collaborative research. Although this list of 46 myositis registries may not be comprehensive, we nevertheless hope that it will be helpful to myositis investigators and enhance collaborative research efforts toward better understanding of these rare autoimmune disorders. In this regard, the principal investigator(s) and their contact information are provided for each registry.
The number and scope of myositis registries have grown substantially over the past several decades. This is leading to larger studies to enable approaching research questions with adequate statistical power. The multicenter national and international registries and their linkage to large biorepositories allow new research questions to be evaluated. Among the 46 registries, we estimate that there are currently more than 30 000 myositis patients involved, although there may be overlap in the enrollment of patients among some studies.
We have categorized this listing of myositis research registries into different groups (Tables 1-3) [13 sitis included, as well as whether the registries are regional, national, or international in scope. Thirteen registries are international, and 33 are national or regional registries. Sixteen registries include all types of myositis, with a predominance of adult forms of myositis (Table 1) , 19 include only adult forms of myositis (Table 2) , and 11 registries have only juvenile forms of myositis (Table 3) . For the registries in which adult and juvenile types of myositis are included, adults generally outnumber juveniles. Registry sizes vary from fewer than a hundred patients to several thousand. A number of the registries are continuing to enroll patients; thus, the enrollment numbers reflect those at the time this article was prepared for publication. The scope and research questions being asked vary considerably, with the most common research focusing on clinical features, phenotype definitions, epidemiology, outcomes, assessment of disease activity, treatment responses, and pathogenesis. The majority of registries (37 of 46) also have associated biorepositories. Sera or plasma samples are the most common specimens collected, but DNA and muscle biopsies are often banked, and skin biopsies, calcinosis specimens, and RNA are available in some.
The largest myositis registry to date, Euromyositis (https://www.euromyositis.eu/), was established in 2008 as a registry for myositis patients, with support from an European Union project 'Autocure' by three European centers with interest in clinical myositis research involved in the Autocure project. The registry has expanded globally through the network Myonet (http://www.myonet.eu) to include 3000 myositis patients, primarily with dermatomyositis and polymyositis, but also including inclusion body myositis (IBM), juvenile dermatomyositis
KEY POINTS
More than 45 myositis research registries, often with associated biorepositories, have enrolled more than 30 000 myositis patients around the world, providing opportunities for collaborative research.
Myositis research registry studies have greatly enhanced our understanding of the clinical and autoantibody phenotypes, outcome assessment, longterm outcomes and prognoses, genetic and environmental risk factors, and pathogenesis of the idiopathic inflammatory myopathies.
Challenges include enhancing the interactions of current myositis registries and biorepositories, developing standards for their maintenance, and obtaining adequate funding to preserve and expand them. ]. To date, the registry has enhanced our understanding of myositis-specific autoantibody (MSA) phenotypes [14, 155] and contributed a large number of samples to the myositis genetics consortium that completed a genome-wide association study [15 & ] in dermatomyositis patients of European descent. Future anticipated work includes the development of prognostic biomarkers, improved serologic testing for myositis autoantibodies, studies of gene-environment interactions, and facilitation of multicenter myositis therapeutic trials.
RESEARCH ADVANCES THROUGH MYOSITIS REGISTRIES AND BIOREPOSITORIES
The development of large myositis registries has led to extensive efforts among a number of studies to carefully phenotype patients based not only on clinical features, but also based on the presence of myositis autoantibodies. These registries have been helpful in refining our knowledge of the spectrum of traditional clinicopathologic [ 86] . These registries should also lead to the recognition of phenotypes that are not currently known.
A study of myositis phenotypes has been undertaken through a large registry that is attempting to define new classification criteria for myositis and its clinicopathologic phenotypes, known as the International Myositis Classification Criteria project. Through the collection of a large number of clinical, demographic, and laboratory variables on almost a thousand myositis patients from around the world, and through use of novel statistical approaches, promising new criteria are emerging to classify myositis and its subgroups that should improve inclusion criteria for natural history and treatment studies and improve our understanding of pathogenesis by using common definitions of these illnesses that have higher sensitivity and specificity [18] .
Through large international collaborative research networks, such as IMACS and the Pediatric Rheumatology International Trials Organisation, new measures have been developed and validated to assess myositis disease activity, manifestations related to reversible inflammatory changes, and damage, that is, the chronic long-term changes associated with previously active disease, as well as illness sequelae and adverse reactions to medications. Core set measures of myositis activity have been agreed upon to be assessed in all therapeutic trials for dermatomyositis, polymyositis, and JDM [101, 119, [123] [124] [125] [126] , and these have been combined to provide preliminary definitions of improvement that represent clinically meaningful change to be used as therapeutic trial endpoints [19, 120, 127] . These core set measures have also been utilized in preliminary definitions of moderate and major response clinical response, representing larger degrees of clinical improvement, and of clinically inactive disease for JDM [121,122 && ]. Consensus in the conduct of myositis clinical trials and standardized therapeutic approaches have also been achieved [99, 156] . These developments have led to standardized reporting of outcomes in therapeutic trials [24] and an increase in the number of myositis therapeutic trials, including trials of new biologic therapies for myositis [80, 102, 103, 120, 133, 157, 158] .
Attention to outcomes beyond the core set measures is a recent development [123] . Standardized assessment of skin activity and damage in myositis through cutaneous assessment tools [20, 72 & ,73,74] has been developed, and assessment of muscle dysfunction, including exercise intolerance [145,150 & ] , and pulmonary and cardiac involvement [71, [146] [147] [148] , is emerging with the use of new, more sensitive radiographic measures. A focus on capturing patient-reported outcomes, including the severe impact of myositis on health-related quality of life, is now beginning [75, 96] . Development of measures for IBM is also receiving attention, as well as standardized muscle biopsy scoring, as a useful adjunct in therapeutic trials or in studies of prognosis [134 & ]. Tools such as the Myositis Damage Index have enabled further understanding of long-term outcomes and the appreciation that most adult and juvenile myositis patients have moderate-to-severe damage on long-term follow-up as well as ongoing active disease [81, 148, 149, 151, 152, 159, 160] . Interest in long-term outcomes and prognosis has also received attention more generally, including the recognition of risk factors for chronic illness course in JDM [35, 104] , associated malignancies or autoimmune overlap syndromes [36,37, [62] of IBM revealed progressive functional disability but no overall increase in mortality. Predictors of mortality for polymyositis, dermatomyositis, and JDM have been determined and were found to be similar in different parts of the world and among phenotypes, with interstitial lung disease and the antisynthetase autoantibodies among the risk factors predicting greater mortality [1 && ,37,67,82]. Classic epidemiologic investigations have been performed, deriving estimates of incidence and prevalence in national registries [3 & ,58], with documented increases in incidence over time for IBM in Australia and an increased prevalence of polymyositis and dermatomyositis in urban regions of Canada, for example [9,10 & ,97,129,138] . Larger registries and repositories have also allowed adequate statistical power to assess other risk factors for myositis. The human leukocyte antigen (HLA) 8.1 ancestral haplotype-A1, B8, DRB1 Ã 0301, DQA1 Ã 0501-has been found to be the strongest immunogenetic risk factor identified to date for all major clinical subgroups of myositis for patients of European ancestry [21,90,91 & ,92, 93, 114, 139, 161] . Nonetheless, MSA phenotypes and some clinical subgroups have distinct HLA risk and protective factors [21, 22, 26, 88, 94, 162] . Through candidate gene studies, additional immune response genes have been identified as risk factors, including PTPN22 [135] , STAT4 [89] , NF-kappaB [27], proinflammatory cytokine polymorphisms of TNFa and IL-1a [115, 140] , immunoglobulin heavy chain phenotypes in JDM, dermatomyositis, polymyositis, and NOTCH4 polymorphisms in IBM [95] . A genome-wide association study [15 & ] that combined specimens from several registries has confirmed the HLA region as the strongest region of risk, but found additional autoimmune loci to be risk factors for dermatomyositis.
Regarding environmental risk factors, ultraviolet radiation has been found to be a risk factor for dermatomyositis and JDM, and its associated autoantibody phenotypes (Mi-2 and anti-TIF1), especially in females [54,116 & ]. Documented infections and other exposures proximal to illness onset, which differ among phenotypes, also suggest environmental factors [141, 163] . For example, the finding, by geospatial clustering analyses, that anti-MDA5 autoantibodies are nonrandomly distributed suggests that environmental factors play a role in this phenotype [49] . Seasonality in onset and birth distributions suggests other environmental factors may be important in pathogenesis [117] . A lack of association with enteroviruses has been documented [139] . A gene-environment interaction study suggested an interaction of smoking with the DRB1 Ã 03 risk factor in patients with antisynthetase autoantibodies [17] , and the DRB1 Ã 1101 allele has been associated with hydroxymethylglutaryl-coenzyme A reductase autoantibodies that may follow statin use [31] . Additional work on gene-environmental interactions should be possible through large registries of carefully phenotyped patients (with biospecimens) for whom common environmental data are also collected, as is being done in Euromyositis, UK Myonet, and other registry studies.
Collections of detailed clinical data and associated biospecimens by investigators have been invaluable in helping us understand many aspects of pathogenesis and in developing biomarkers of disease. Examples include the discovery of the primary role of plasmacytoid dendritic cells and the interferon signature in the pathogenesis of dermatomyositis and JDM muscle and skin disease in several populations [ & ], and the pathogenesis of endothelial activation [105] , muscle regeneration [106] and calcifications [107] in JDM have also been examined.
MYOSITIS PATIENT SUPPORT GROUP REGISTRIES
Myositis patient support groups also maintain registries of patients and data, primarily consisting of demographic information, diagnoses, and contact information. Such patient databases are potentially valuable resources to enable patients to be contacted to inform them of newly approved research studies for which they may be eligible to participate. The Myositis Association (www.myositis.org), a US-based, international patient support group for all forms of myositis, maintains a database of almost 8000 patients with dermatomyositis, polymyositis, IBM, and JDM, which also includes basic demographic and contact information. The Cure JM Foundation (www.curejm.org), a US-based support group for juvenile myositis, maintains an electronic database with demographic information of more than 1300 juvenile myositis patients. Cure JM has epidemiologic research goals, including examining possible geographic clustering of cases. The Muscular Dystrophy Association has initiated a research registry program for neuromuscular diseases through their clinics. Starting with 25 pilot clinics and several neuromuscular disorders (amyotrophic lateral sclerosis, Duchenne muscular dystrophy, and spinal muscular atrophy), they plan to register up to 3500 patients in an initial phase and expand this to additional neuromuscular disorders, including myositis, and involvement of all their clinics in a national network [165 & ]. The research goals of the Muscular Dystrophy Association's neuromuscular registry program include understanding the course of illness through the collection of longitudinal data, benchmarking best clinical practices, implementing a quality improvement program, collecting data about genotype-phenotype correlations to allow better prediction of disease progression, and to facilitate clinical trial recruitment.
Recently, two large national (United States) myositis patient research registries have been established, which include some patients from other countries, particularly Canada. The Myositis Association has established a registry called MYOVISION, which contains information from almost 2000 patients with dermatomyositis, polymyositis, IBM, and JDM. Demographic, clinical, and treatment information, associated environmental exposures and quality-of-life information were obtained in a recent patient questionnaire. A second registry, the Yale University IBM Registry, led by Dr A. David Paltiel, has enrolled 950 patients with IBM from the United States and Canada, capturing patient-reported demographic and clinical features as well as activities of daily living information. Although the data collection has been retrospective, the investigators hope this information will serve as the basis for a prospective patient registry, as well as inform the development of basic information about disease progression and other issues of interest to patients, caregivers, and physicians. Both registries are currently analyzing their findings.
CHALLENGES AND BENEFITS OF REGISTRIES AND BIOREPOSITORIES
Myositis registries have become tremendous resources and have provided a wealth of new research findings and opportunities for future research. Myositis researchers may collaborate with existing registries, including the possibility of depositing their data with some registries, such as Euromyositis or the IMACS Outcomes Repository. New registries may examine genetic and/or environmental factors of geographically isolated populations that may provide insights into the geoepidemiology of myositis. Much work remains to be done within existing registries to bring to fruition new research findings from the large volumes of data and samples already gathered.
The proliferation of registries and biorepositories for myositis has also generated a number of challenges. Inconsistencies in the classification and diagnostic criteria of myositis and its subgroups among studies, lack of use of standardized terms and variables for the databases, collection of varying data elements and biobank specimens, and variations in assays for myositis autoantibodies and other biomarkers -all make comparisons of the findings among various studies difficult and complicate combining data among registry studies to enhance statistical power for research questions. Use of appropriate standards to maintain biorepositories [166] and appropriate informed consent for new genetic testing, as well as differences in national and international rules for data sharing between studies are some other noted challenges. Although myositis registries have become tremendous resources and have provided a wealth of new research, more stable funding is required to maintain and expand these databases and biorepositories. The involvement of patient support groups and other private foundations and donors is needed, with recognition of the importance of these resources for future efficient research in myositis.
CONCLUSION
The establishment of larger collections of patients with detailed clinical outcome, and other data, often linked to biospecimens, has enabled more rapid progress in myositis clinical and translational research over the past several decades. We expect the further growth of these national and international registries to lead to expanded understandings of myositis phenotypes, outcomes and prognoses, genetic and environmental risk factors, including gene-environment interactions, and pathogenesis, all of which could lead to more effective new therapies, and even the prospect of preventing some forms of myositis in the future. The era of single investigator research has yielded great advances in many areas of myositis, but future studies will require collaborations not only among multiple investigators within a single registry, but also among multiple registry studies, to allow the most costeffective and timely advances in our understanding of myositis. The aim of this work was to examine the risk factors for mortality in juvenile myositis patients. The authors found that the overall mortality was higher in juvenile myositis patients. The importance of the study is that they also identified the top mortality risk factors: antisynthetase autoantibodies, older age at disease onset, interstitial lung disease, and Raynaud's phenomenon. The aims of the present study were to assess the flow-mediated dilatation of the brachial artery by a TensioClinic arteriograph and to measure the thickness of carotid artery intima-media, the augmentation index, and the pulse wave velocity using highresolution ultrasonography in a cohort of polymyositis and dermatomyositis patients. The correlation of these parameters with the traditional risk factors of atherosclerosis and overall cardiovascular status within polymyositis and dermatomyositis patients were also investigated. The findings suggest that flow-mediated dilatation of the brachial artery, arterial stiffness, and carotid artery thickness measurements could be helpful in predicitng the cardiovascular risk in myositis patients. A large cohort from Australia that examines the coassociation of myositis and cancer over the past 30 years. Lung and prostate cancer were the most common; almost 30% of cancers occurred within 1 year of myositis diagnosis. Risk factors for cancer were as follows: shawl sign rash, male gender, and rheumatoid arthritis; myalgia was a protective factor. 69.
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